3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Cholangiocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pharyngeal Neoplasms
1
Oropharyngeal Neoplasms
1
Oligometastatic Prostate Cancer
1
Mouth Neoplasms
1
Melanoma
1
Lung Diseases
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
trametinib
8
dabrafenib
7
pembrolizumab
5
Paclitaxel
5
lenvatinib
4
Radiotherapy, Intensity-Modulated
3
Doxorubicin
3
fosbretabulin
2
cobimetinib
2
cemiplimab
2
atezolizumab
2
Vemurafenib
2
Sorafenib
2
Nivolumab
2
Bevacizumab
2
zimberelimab
1
tremelimumab
1
selpercatinib
1
sapanisertib
1
sacituzumab govitecan
1
pegfilgrastim
1
fludarabine
1
efatutazone
1
durvalumab
1
ceritinib
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Thyroidectomy
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thyroid Carcinoma, Anaplastic
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled